

1 Global Burden of Disease worldwide cohort analysis of
2 dietary and other risk factors for cardiovascular diseases:
3 lipid hypothesis versus fat-soluble vitamin hypothesis

4 David K Cundiff (0000-0002-3206-9665), independent researcher,^{1,3} Chunyi Wu (0000-0002-
5 2186-3433), Research Epidemiologist/Statistician,^{2,3}

6 1 Long Beach, California, USA

7 2 Area Specialist Lead in Epidemiology and Statistics, Michigan Medicine, Ann Arbor,
8 Michigan, USA

9 3 Volunteer collaborators with the Institute of Health Metrics and Evaluation, Seattle,
10 Washington, USA

11 Correspondence to David K Cundiff davidkcundiff@gmail.com Phone: 01-562-438-8805

12 Word count: abstract 389, Text: 4574

13

14

15 **Abstract**

16 **Background** Regarding diet's contribution to cardiovascular disease, Ancel Keys, MD proposed
17 his "lipid hypothesis" in the 1950s. Despite USDA Dietary Guidelines endorsing the lipid
18 hypothesis, debate about whether dietary saturated fat and cholesterol cause cardiovascular
19 disease has continued.

20

21 **Methods** Using Global Burden of Disease (GBD 2017) data on cardiovascular disease
22 deaths/100k/year, ages 15-69 years old in male and female cohorts (CVD) and dietary and other
23 risk factors, we formatted and population weighted data from 195 countries. Each of the resulting
24 7846 rows of data (cohorts) represented about 1 million people, projected to total about 7.8
25 billion people in 2020. We correlated CVD with dietary and other risk factors worldwide and in
26 appropriate subsets.

27

28 **Findings** All foods were expressed in kilocalories/day (KC/d). We summed the KC/d of
29 processed meat, red meat, fish, milk, poultry, eggs, and added (saturated fatty acid,
30 polyunsaturated fatty acid, and trans fatty acid) to create a "fat-soluble vitamins variable"
31 (FSVV) high in vitamins A, D, E, and K2 (menaquinones). Low density lipoprotein cholesterol
32 (LDL-c) correlated positively with LSVV worldwide ($r=0.780$, 95% CI 0.771 to 0.788,
33 $p<0.0001$, $n=7846$ cohorts), so we considered LSVV our marker variable to test the lipid
34 hypothesis as well as our fat-soluble vitamin hypothesis. The FSVV correlated negatively with
35 CVD worldwide ($r= -0.329$, 95% CI -0.349 to -0.309, $p<0.0001$), and FSVV correlated
36 positively with CVD in high FSVV cohorts (when $FSVV \geq 567.3$ KC/d: $r=0.523$, 95% CI 0.476 to
37 0.567, $p<0.0001$, $n=974$ cohorts). Meat and poultry negatively correlated with CVD worldwide

38 (e.g., red meat mean=50.27 KC/d, $r = -0.232$, 95% CI -0.253 to -0.211, $p < 0.0001$) and positively
39 with CVD in high FSVV cohorts (e.g., red meat mean=122.2 KC/d, $r = 0.655$, 95% CI 0.618 to
40 0.690, $p < 0.0001$, $n = 974$ cohorts).

41
42 **Interpretation:** Since FSVV correlated positively with CVD in high FSVV cohorts
43 ($FSVV \geq 567.3$ KC/d, $n = 974$ cohorts), the lipid hypothesis is supported only in GBD cohorts and
44 individuals with high FSVV intake. These data support the fat-soluble vitamins hypothesis
45 because FSVV correlated negatively with CVD worldwide, meaning the more fat-soluble
46 vitamin containing animal foods and fat for gut absorption the less the CVD. In high FSVV
47 countries, reducing meat and poultry intake by at least half would likely reduce CVD
48 significantly. This GBD cohort methodology could supplement prospective observational studies
49 of individuals to be used in developing food policy and education strategies for reducing CVD
50 and improving public health.

51 **Funding:** None

52

53

54 **Research in context**

55 **Evidence before this study**

56 In the field of nutritional epidemiology, controversies abound. The lipid hypothesis that dietary
57 saturated fat and cholesterol promote cardiovascular diseases has been disputed recently with no
58 scientific consensus on the outcome.

59

60 **Added value of this study**

61
62 With worldwide GBD data, we created a fat-soluble vitamins variable (FSVV) with animal
63 foods—the primary source of fat-soluble vitamins—and fatty acids—the vehicle for absorption
64 of vitamins A, D, E, and K. We found a strong positive correlation between LDLc and FSVV
65 worldwide. Consequently, we used FSVV to test both the lipid hypothesis and our fat-soluble
66 vitamin hypothesis. CVD correlated negatively with FSVV worldwide, meaning insufficient fat-
67 soluble vitamin containing animal food and added fatty acid intake associated with increased
68 CVD. In the subset with high FSVV ($FSVV \geq 567.3$, $n=974$ cohorts), CVD positively correlated
69 with FSVV, suggesting that excessive saturated fat and cholesterol containing food and added
70 fatty acids associates with increased CVD.

71

72 Low poultry and meat intake associated with higher CVD worldwide (i.e., mean processed
73 meat=5.3 KC/d, red meat=50.3 KC/d, poultry=44.3 KC/d). However, in high FSVV countries,
74 high meat and poultry intakes associated with higher CVD (i.e., with $FSVV \geq 567.3$ KC/d, mean
75 processed meat=25.0 KC/d, mean red meat=122.2 KC/d, mean poultry=130.0 KC/d, $n=974$
76 cohorts). Eggs, fish, and milk products in any amount associated with lower CVD.

77

78 **Implications of all the available evidence**

79 The data support the fat-soluble vitamin hypothesis worldwide and the lipid hypothesis only in
80 high FSVV cohorts and individuals. These findings are plausible because deficiencies of
81 vitamins A, D, E, and K (fat soluble vitamins) and fatty acids, required for gut absorption, have
82 been documented to lead to cardiovascular adverse effects. These findings are consistent with the
83 lipid hypothesis in individuals within high FSVV intake countries (e.g., Seven Country Study
84 and Framingham Heart Study). In high FSVV countries, such as in the USA and Europe, the data
85 suggest that public health strategies should endeavor to promote reduction of animal foods and
86 added fats, particularly meat and poultry consumption. In developing countries with low FSVV
87 intake, supplemental fat-soluble vitamin intake should be studied. This GBD data-based
88 methodology can enhance understanding of the complex interrelationships of dietary and other
89 risk factors with CVD and other health endpoints.

90

91 **Introduction**

92 The Seven Countries Study, led by Ancel Keys, an epidemiologist from the
93 University of Minnesota and the lipid hypothesis' major proponent, involved 12,763
94 males, 40–59 years of age, in seven countries, in four regions of the world (United
95 States, Northern Europe, Southern Europe, and Japan) beginning in 1958.¹ All these
96 regions had relatively high animal food intake compared with the rest of the world.
97 The study concluded that dietary saturated fatty acid leading to
98 hypercholesterolemia was a major cause of coronary artery disease (CAD). Two
99 concerns with the lipid hypothesis are that middle-aged males in these countries may
100 not be representative of CAD or overall cardiovascular disease epidemiology
101 worldwide and that tobacco smoking (a major risk factor for CAD) also raises serum
102 cholesterol. Randomized trial data of lipid lowering drug treatment have also been
103 much less than consistently supportive of its efficacy in lowering CVD.²

104

105 The scientific validity of the Dietary Guidelines for Americans for 2015-2020, including
106 guidelines based on the lipid hypothesis, was challenged by Journalist Nina Teicholz in the
107 *BMJ*.³ The Center for Science in the Public Interest called for the *BMJ* to retract the article. The
108 peer reviewers the *BMJ* selected to adjudicate the far reaching dispute concluded that,
109 “Teicholz’s criticisms of the methods used by Dietary Guidelines for Americans Committee are
110 within the realm of scientific debate.”⁴

111

112 We define the fat-soluble vitamin hypothesis as, “suboptimal dietary intake of fat-
113 soluble vitamins and added fat for gut absorption increases cardiovascular diseases.”

114 Fat-soluble vitamins include vitamins A, D, E, and K (K1=phylloquinones and K2=
115 menaquinones). Vitamin A and its beta-carotene precursor are important in preventing congenital
116 heart disease.^{5,6} Vitamin E protects the vasculature against oxidative stress, including lipid
117 peroxidation and the production of atherogenic forms of LDLc—a part of the pathogenesis of
118 cardiovascular disease.⁷ Vitamin K2 (menaquinones from animal foods and fermented plant
119 products) inhibits arterial calcification, a major factor in the pathogenesis of atherosclerosis and
120 cardiovascular disease.⁸ Regarding vitamin D, a meta-analysis showed an inverse
121 association between cardiovascular disease and circulating 25(OH)-vitamin D
122 ranging from 20 to 60 nmol/L.⁹ The four fat-soluble vitamins come primarily from
123 animal foods. Vitamin K2 levels are high in aged cheeses, other fermented dairy
124 products,¹⁰ organ meats (e.g., bovine and pork liver), chicken, and egg yolks.¹¹ The
125 highest vitamin K2 levels per 100g serving are in fermented legumes, particularly
126 soy (e.g., natto and miso (Japan),^{12,13} soybean Douchi, soybean Meitauza, and soybean curd
127 (China and Taiwan),¹⁴ and Cheonggukjang, a fermented soybean stew (South Korea)).¹⁵

128
129 This paper will use population weighted, formatted worldwide Global Burden of Disease data
130 from 2017 (GBD 2017) from the Institute of Health Metrics and Evaluation (IHME) to assess the
131 impact of dietary and other risk factors on cardiovascular disease early deaths.

132

133 **Methods**

134 As volunteer collaborators with the IHME, we utilised raw GBD worldwide ecological data
135 (GBD 2017: 195 countries and 365 subnational locations (n=1120 male and female cohorts)).
136 Data consisted of the rate of cardiovascular disease early deaths, metabolic risk factors, dietary
137 risk factors and covariates, and other risk factors of male and female cohorts 15-49 years old and
138 50-69 years old from each year 1990-2017. For cardiovascular disease early deaths and all risk
139 factors, we averaged the values for ages 15-49 years old together with 50-69 years old for each
140 male and female cohort for each year. Finally, for each male and female cohort, data from all 28
141 years (1990-2017) of the means of the rate of cardiovascular disease early deaths and risk factor
142 exposures were averaged using the computer software program R. We defined the rate of
143 cardiovascular disease early deaths as “deaths/100k/year of males and females 15-69 years old”:
144 abbreviated CVD.

145
146 Food risk factors came from IHME as gram/day (g/d) consumed per capita. GBD dietary
147 covariate data originally came from Food and Agriculture Organization surveys of animal and
148 plant food commodities available per capita in countries worldwide (potatoes, corn, rice, sweet
149 potatoes, poultry, and eggs)—as opposed to consumed per capita.¹⁶ Supplementary Table 1 lists
150 the relevant GBD risk factors, covariates, and other available variables with definitions of those
151 risk factor exposures.¹⁷

152
153 GBD worldwide citations of over 12,000 surveys constituting ecological data inputs for this
154 analysis are available online from IHME.¹⁶ The main characteristics of IHME GBD data sources,
155 the protocol for the GBD study, and all risk factor values have been published by IHME GBD

156 data researchers and discussed elsewhere.¹⁸⁻²¹ These include detailed descriptions of categories
157 of input data, potentially important biases, and the methodologies of analysis. We did not clean
158 or pre-process any of the GBD data. GBD cohort risk factor and health outcome data from the
159 IHME had no missing records. Because the GBD data for the study came from IHME, no ethics
160 committee approval or institutional review board review was needed for this post hoc statistical
161 analysis. Once IHME staff time constraints due to COVID-19 data collection and modeling are
162 over, the updated GBD 2019 data with all the variables as the GBD 2017 data we used for this
163 analysis may be obtained by volunteer researchers collaborating with IHME.²²

164
165 To weigh the data according to population, internet searches (mostly Wikipedia) yielded the
166 most recent population estimates for countries and subnational states, provinces, and regions.
167 The 1120 GBD cohorts available were population weighted by a software program in R resulting
168 in an analysis dataset with 7846 population weighted cohorts representing about 7.8 billion
169 people in 2020. Each male or female cohort in the population-weighted analysis dataset
170 represented approximately 1 million people (range: < 100,000 to 1.5 million). For example, India
171 with about 1.234 billion people had 617 rows of the same data for males and 617 rows for
172 females. Maldives, with about 445,000 people, had a single row of data for males and another for
173 females. Without population-weighting the data, cohorts in India and Maldives each would have
174 had one row for males and one row for females in the analysis dataset, invalidating the analysis
175 results. World population data from the World Bank or the Organisation for Economic Co-
176 operation and Development could not be used because they did not include all 195 countries or
177 any subnational data.

178

179 This report followed the STrengthening the Reporting of OBservational studies in Epidemiology
180 (STROBE) guidelines for reporting global health estimates (Supplementary Table 2).²³

181
182 Supplementary Table 3 details how omega-3 fatty acid g/d was converted to fish g/d using data
183 on the omega-3 fatty acid content of frequently eaten fish from the National Institutes of Health
184 Office of Dietary Supplements (USA).²⁴ As shown in Supplementary Table 4, we converted all
185 of the animal and plant food data, including alcohol and sugary beverage consumption, from g/d
186 to kilocalories/day (KC/d). For the g/d to KC/d conversions, we used the Nutritionix track app,²⁵
187 which tracks types and quantities of foods consumed. Saturated fatty acids (0-1 portion of the
188 entire diet) was not available with GBD 2017 data, so GBD saturated fatty acids risk factor data
189 from GBD 2016 was used. Polyunsaturated fatty acid and trans fatty acid GBD risk factor data
190 from 2017 (0-1 portion of the entire diet) were also utilised, but monounsaturated fat data were
191 not available. These fatty acid data expressed as 0-1 portion of the entire diet were converted to
192 KC/d by multiplying by the total KC/d available per capita for each cohort.

193
194 The principal outcome variable, CVD, was a combination variable consisting of the
195 deaths/100k/year from ischemic heart disease, stroke, hypertensive heart disease, rheumatic heart
196 disease, non-rheumatic valvular disease, subarachnoid haematoma, myocarditis, alcoholic
197 cardiomyopathy, endocarditis, aortic aneurysm, and atrial fibrillation.

198

199 **Statistical methods**

200 To determine the strengths of the risk factor correlations with CVD of population weighted
201 worldwide cohorts (n=7846 cohorts) or subgroups of cohorts (e.g., highest and lowest CVD

202 cohorts, etc.), we utilised Pearson correlation coefficients: r , 95% confidence intervals (CIs), and
203 p values.

204

205 We used SAS and SAS OnDemand for Academics software 9.4 (SAS Institute, Cary, NC) for the
206 data analysis.

207 **Results**

208 Table 1 shows the 43 dietary and other risk factors potentially contributing to CVD. See
209 Supplementary Table 1 for definitions of the risk factor and co-variate variables. LDLc
210 negatively correlated with CVD worldwide ($r=-0.279$, 95% CI -0.299 to -0.258, $p<0.0001$, Table
211 1), meaning the higher the LDLc mmol/L the lower the CVD. Figure 1 gives the worldwide plot
212 of LDLc versus CVD, showing widely scattered data points.

213
214 To test the fat-soluble vitamin hypothesis, we summed the KC/d of processed meat, red meat,
215 fish, milk (including all dairy products), poultry, eggs, and added fat (saturated fatty acid (SFA),
216 polyunsaturated fatty acid (PUFA), and trans fatty acid (TFA)) to create a fat-soluble vitamins
217 variable (FSVV). In determining the portion of SFA, PUFA, and TFA added in addition to the
218 SFA, PUFA, and TFA in the animal and plant foods, an adjustment factor (fatty acids * 0.46),
219 adapted from the website “Our World in Data,” differentiated the fatty acids in individual foods
220 from the added fatty acids (46% of the total).²⁶ This adjustment prevented double counting fatty
221 acids KC/d and allowed a reasonably accurate determination of FSVV KC/d. The FSVV
222 negatively correlated with CVD worldwide ($r=-0.329$, 95% CI -0.349 to -0.309, $p<0.0001$, Table
223 1), meaning more FSVV KC/d (processed meats KC/d + red meats KC/d + fish and seafood
224 KC/d + milk KC/d + poultry KC/d + eggs KC/d + added fatty acids) associated with reduced
225 CVD.

226
227 Table 1 shows that six of the nine plant foods negatively correlated with CVD. Potatoes (KC/d
228 available, a covariate derived from total potato KC available/population, including highly
229 processed potatoes) positively correlated with CVD ($r=0.050$, 95% CI 0.028 to 0.073, $p<0.0001$).

230 Sugary beverages also correlated positively with CVD ($r=0.113$, 95% CI 0.091 to 0.135,
231 $p<0.0001$). Rice and legumes were not significantly correlated with CVD.

232

233 Child underweight, ambient air pollution, smoking tobacco, sublingual tobacco use, kidney
234 disease, types 1 and 2 diabetes deaths, and systolic blood pressure all positively correlated with
235 CVD. Sex (male 1 and female 2) negatively correlated with CVD, meaning females had less
236 CVD risk than males.

237

238 Table 2 is a subset of worldwide cohorts that included 500 male and female pairs of cohorts
239 (total=1000 cohorts, an arbitrary number, representing approximately 1 billion people out of
240 about 7.8 billion people worldwide) with the lowest CVD values ($CVD \leq 293.0$ compared with
241 mean $CVD=543.7$ worldwide).

242

243 Table 3 shows FSVV related risk factors (processed meat, red meat, fish, milk, poultry, eggs, and
244 added (SFA+PUFA+TFA)) for the 34 countries in descending order by CVD. Japan, with the
245 lowest CVD worldwide ($CVD=169.2$), had the highest KC/d for fish and eggs (fish=260.5 KC/d
246 and eggs=53.2 KC/d) and otherwise relatively low values for meat, milk and poultry. The
247 countries with $FSVV < 300$ KC/d tended to be clustered at the high CVD end of the Table 3 (i.e.,
248 Guatemala: $FSVV=231.1$ and $CVD=269.9$, Kenya: $FSVV=150.04$ and $CVD=270.0$, Nicaragua:
249 $FSVV=214.2$ and $CVD=282.0$, Tehran (Iran): $FSVV=299.7$ and $CVD=283.3$, and Thailand:
250 $FSVV=247.4$ and $CVD=289.9$).

251

252 Table 4 gives all the CVD risk factors for seven representative countries out of the 34 countries
253 in Tables 2 and 3 ($CVD \leq 293.0$). Japan not only had high FSVV but also had relatively high
254 intake of GBD risk factor plant foods (fruits, vegetables, nuts and seeds, whole grains, and
255 legumes: 350.9 KC/d). France was characteristic of 23 other low CVD countries in that intake of
256 milk products was high (France milk=95.8 KC/d and the other 23 countries' milk>68 KC/d,
257 Table 3). The low CVD of Peru might be attributed to a relatively low smoking rate (7.5%) and
258 good metabolic statistics (mean BMI=23.3 Kg/M², mean FPG=4.01 mmol/L, mean LDLc=2.37
259 mmol/L, mean SBP=125.2 mm/Hg). While Mexico had a lower FSVV than most low CVD
260 countries (Mexico FSVV=413.3 KC/d), like Japan it had relatively high intake of important plant
261 foods (fruits, vegetables, nuts and seeds, whole grains, and legumes: totaling 351.7 KC/d).
262 Panama, with FSVV=383.8 KC/d, had relatively high physical activity (Panama physical
263 activity=4935 METs) and low smoking rate (male/female mean smoking=7.3%). While
264 Guatemala had relatively low FSVV (FSVV=231.1 KC/d) and low GBD risk factor plant food
265 intake (fruits, vegetables, nuts and seeds, whole grains, and legumes: 249.5 KC/d), it had
266 relatively high physical activity (physical activity=6142 METs) and a low smoking rate
267 (male/female mean smoking=7.7%). Ecuador had an intermediary FSVV (FSVV=375.4 KC/d)
268 and relatively low intake of important plant foods (fruits, vegetables, nuts and seeds, whole
269 grains, and legumes: totaling 205.3 KC/d). However, Ecuador had a low rate of smoking
270 (male/female mean smoking=8.0%). and a low SBP (mean SBP=126.9 mm/Hg).

271
272 Table 5 shows the statistics for countries with $FSVV \geq 567.3$ KC/d (i.e., at or above the median
273 FSVV of Table 2 countries). In this subset of 974 cohorts, of which 500 were included in the low

274 CVD subset (Table 2), FSVV positively correlated with CVD ($r=0.523$, 95% CI 0.476 to 0.567,
275 $p<0.0001$).

276

277 Although FSVV correlated strongly with LDLc worldwide ($r=0.780$, 95% CI 0.771 to 0.788,
278 $p<0.0001$, $n=7846$ cohorts, Table 1), FSVV negatively correlated with LDLc in cohorts with
279 $FSVV \geq 567.3$ KC/d ($r=-0.254$, 95% CI -0.312 to -0.194, $p<0.0001$, $n=974$ cohorts). Also with
280 $FSVV \geq 567.3$ KC/d, LDLc and CVD negatively correlated ($r=-0.254$, 95% CI -0.312 to -0.194,
281 $p<0.0001$, $n=974$ cohorts).

282

283 The average alcohol intake was 81.0 KC/d worldwide, and alcohol KC/d correlated negatively
284 with CVD ($r=-0.061$, 95% CI -0.083 to -0.039, $p<0.0001$, Table 1). However, with the higher
285 mean alcohol KC/d intake of 155.0 KC/d in cohorts with $FSVV \geq 567.3$ KC/d, alcohol was
286 positively correlated with CVD ($r=0.475$, 95% CI 0.425 to 0.522, $p<0.0001$, $n=974$ cohorts,
287 Table 5).

288

289 The only fat-soluble vitamin in the GBD database, vitamin A deficiency incidence/100k in
290 children ≤ 5 years old, correlated positively with CVD worldwide ($r=0.210$, 95% CI 0.189 to
291 0.231, $p<0.0001$, Table 1). In the cohorts with $FSVV \geq 567.3$ KC/d who had high intakes of
292 vitamin A presumably from animal foods, vitamin A deficiency rate in children ≤ 5 years old
293 was much lower compared with worldwide (Vitamin A deficiency=9316/100k/year, Table 5
294 versus 23,205/100k/year, Table 1).

295

296 Dietary fiber was not significantly correlated with CVD worldwide ($r=0.019$, 95% CI -0.003 to
297 0.041 , $p=0.09$, Table 1). Once it was adjusted for FSVV, alcohol, sugary beverages, and
298 potatoes; dietary fiber correlated negatively with CVD ($r=-0.052$, 95% CI -0.074 to -0.030 ,
299 $p<0.0001$).

300

301 Physical activity positively correlated with CVD worldwide ($r=0.160$, 95% CI 0.139 to 0.182 ,
302 $p<0.0001$, Table 1). Once it was adjusted for FSVV, smoking, and sex; physical activity
303 correlated negatively with CVD ($r=-0.127$, 95% CI -0.149 to -0.104 , $p<0.0001$).

304

305 Discontinuing breast feeding before 6 months negatively correlated with CVD worldwide ($r=-$
306 0.302 , 95% CI -0.322 to -0.282 , $p<0.0001$, Table 1). Once we adjusted it for FSVV, child severe
307 underweight, and socio-demographic index, discontinuing breast feeding correlated positively
308 with CVD ($r=0.044$, 95% CI 0.022 to 0.066 , $p<0.0001$). In cohorts, mostly in developed
309 countries, with FSVV ≥ 567.3 KC/d discontinuing breast feeding correlated positively with CVD
310 ($r=0.268$, 95% CI 0.208 to 0.325 , $p<0.0001$, Table 5).

311

312 Secondhand smoking negatively correlated with CVD worldwide ($r=-0.225$, 95% CI -0.246 to -
313 0.204 , $p<0.0001$, Table 1). Once it was adjusted for smoking, sublingual tobacco use, household
314 smoke, ambient air pollution, and sex; secondhand smoke correlated positively with CVD
315 ($r=0.048$, 95% CI 0.025 to 0.070 , $p<0.0001$).

316

317 The metabolic risk factors, BMI, FPG, and LDLc, all correlated negatively with CVD worldwide
318 ($r=-0.240$, 95% CI -0.261 to -0.219 , $p<0.0001$, $r=-0.178$, 95% CI -0.200 to -0.157 , $p<0.0001$, and
319 $r=-0.279$, 95% CI -0.299 to -0.258 , $p<0.0001$, respectively, Table 1). Once they were
320 adjusted for FSVV, alcohol, sugary beverages, and potatoes; they all correlated positively with
321 CVD ($r=0.028$, 95% CI 0.006 to 0.050 , $p=0.0144$, $r=0.076$, 95% CI 0.054 to 0.098 , $p<0.0001$,
322 $r=0.170$, 95% CI 0.148 to 0.191 , $p<0.0001$, respectively). In the cohorts with $FSVV \geq 567.3$
323 KC/d, BMI and FPG positively correlated with CVD ($r=0.484$, 95% CI 0.434 to 0.530 , $p<0.0001$
324 and $r=0.091$, 95% CI 0.028 to 0.153 , $p=0.0046$, respectively).
325

326 **Discussion**

327 Why, in high FSVV cohorts, LDL-c correlated negatively with FSVV ($r=-0.254$ 95% CI -0.312
328 to -0.194, $p<0.0001$, $n=974$ cohorts) but positively correlated with LSVV worldwide ($r=0.780$,
329 95% CI 0.771 to 0.788, $p<0.0001$) is not entirely clear. However, multiple studies have
330 documented that LDLc may be influenced by genetic, racial, or ethnic differences that do not
331 necessarily correspond with risk of CVD.^{27,28} Additionally, LDLc lowering medications in wide
332 use especially in high FSVV developed countries may also confound the relationship of LDLc
333 with CVD risk in this subset cohort analysis. Because of this anomaly with LDLc correlated with
334 FSVV in high FSVV cohorts and the strong worldwide correlation of LDLc and FSVV, we
335 considered FSVV positively correlating with CVD as supporting the lipid hypothesis and FSVV
336 negatively correlating with CVD as supporting the fat-soluble vitamin hypothesis.

337
338 With this perspective, in high FSVV cohorts ($FSVV \geq 567.3$ KC/d, $n=974$ cohorts) where FSVV
339 positively correlated with CVD ($r=0.523$ 95% CI 0.476 to 0.567, $p<0.0001$, $n=974$ cohorts), this
340 analysis strongly supports the lipid hypothesis. Since there are high FSVV and low FSVV people
341 widely distributed worldwide, prospective observational studies of individuals in high FSVV
342 areas, rather than GBD cohort studies, could better demonstrate positive correlations between
343 LDLc (or total cholesterol) and CVD. This may explain why the Seven Countries Study¹ of
344 Ancel Keys and the Framingham Heart Study,²⁹ both in high FSVV regions, validated the lipid
345 hypothesis. However, the Prospective Urban Rural Epidemiology (PURE) Study, with individual
346 data on 135,335 patients from three high-income, 11 middle-income, and four low-
347 income countries appears to be at variance with the lipid hypothesis.³⁰ The PURE Study found
348 that higher saturated fat intake was associated with lower risk of stroke (quintile 5 vs quintile 1,

349 HR 0.79, (95% CI 0.64 to 0.98), $p_{\text{trend}}=0.0498$). Total fat, saturated fat, and unsaturated fats were
350 not significantly correlated with risk of myocardial infarction or cardiovascular disease mortality.
351 Exclusively high FSVV populations appear necessary for lipid hypothesis validation.

352

353 This global data analysis supports the fat-soluble vitamin hypothesis or possibly another
354 mechanism that accounts for FSVV KC/d being negatively correlated with CVD worldwide ($r=-$
355 0.308 , 95% CI -0.358 to -0.257 , $p<0.0001$, Table 1). If the fat-soluble vitamins hypothesis is
356 valid and augmentation of fat-soluble vitamins is not widely provided, the worldwide FSVV
357 KC/d mean consumption must increase about 85% to minimise CVD (mean FSVV= 288.1 KC/d
358 worldwide (Table 1) * $1.85\approx 531.4$ KC/d (mean FSVV=531.4 KC/d, Table 2)). In the subset of
359 974 cohorts (≈ 1 billion people) with $\text{FSVV}\geq 692.6$ KC/d (Table 5), to minimise CVD, FSVV
360 KC/d mean consumption should be reduced on average by about 23% (692.6 mean KC/d (Table
361 5) * $0.77\approx 531.4$ mean KC/d (presumed optimal FSVV). To minimise CVD in the USA, FSVV
362 KC/d mean consumption should be reduced on average by about 36% (828.8 mean KC/d *
363 $0.64\approx 531.4$ mean KC/d (presumed optimal FSVV, Table 2).

364

365 Given the negative correlations of CVD with both fish and eggs in both tables 1 and 5, the
366 reduction in FSVV might best come from meat, poultry, and added fats. Although milk
367 correlated positively with CVD in Table 5 ($r=0.185$, 95% CI 0.123 to 0.245 , $p<0.0001$), this
368 probably relates to Japan and Peru having the lowest and fifth lowest CVD in Table 3 (Japan:
369 mean CVD=169.2, mean milk=29.0 KC/d, Peru: mean CVD=197.7, mean milk=15.3 KC/d). Of
370 the 34 countries in Table 3, 20 had high milk intakes (mean milk ≥ 68.8 KC/d versus mean milk
371 worldwide=25.0 KC/d) and these all had relatively high per capita intakes of cheese.^{31,32}

372 Fermented, full-fat dairy products have high levels of vitamin K2,^{10,11} which have been found to
373 be important in preventing calcification of arteries and atherosclerosis.³³

374

375 Regarding the Japanese low CVD and low milk KC/d (29.0 KC/d), fish and eggs might be
376 possible sources of vitamin K2. However, relative to fermented cheeses and egg yolks, fish
377 content of vitamin K2 is low to negligible.¹¹ Instead, Japanese consume high quantities of
378 vitamin K2 in the form of fermented soy products like natto and miso.^{12,13} As noted in the
379 introduction, people in Taiwan and South Korea (also listed among low CVD countries) also
380 have high intakes of fermented legumes.

381

382 Potatoes KC/d available positively correlated with CVD both worldwide ($r=0.050$, 95% CI 0.028
383 to 0.073, $p<0.0001$, Table 1) and in cohorts with $FSVV\geq 567.3$ KC/d ($r=0.109$, 95% CI 0.046 to
384 0.170, $p<0.0001$, Table 5). Notably, half, or more of the potatoes consumed worldwide are in
385 the form of highly processed food products.³⁴ Recent large prospective observational studies
386 have found higher consumption of ultra-processed foods associated with an increased risk of
387 cardiovascular disease incidence and CVD mortality.^{35,36} Data from 79 high- and middle-income
388 countries show that ultra-processed products dominate the food supplies of high-income
389 countries and that their consumption is now rapidly increasing in middle-income countries.³⁷

390

391 The finding that sodium negatively correlated with CVD worldwide ($r=-0.213$, 95% CI -0.234 to
392 -0.192, $p<0.0001$) is contrary to an analysis of sodium intake versus cardiovascular deaths in 66
393 countries by Mozaffarian, et. al who attributed 9.5% of cardiovascular deaths worldwide to high
394 sodium intake.³⁸ However, O'Donnell and colleagues found the relationship of sodium to

395 cardiovascular disease to be J shaped curve and suggested that the lowest cardiovascular risk is
396 with moderate sodium intake in the 3-5 g/d range.³⁹ In this IHME GBD database, the Japanese
397 had one of the highest levels of dietary sodium (mean sodium excretion =6.01 g/d versus mean
398 mean sodium excretion worldwide=4.45 g/d) along with high rates of smoking (Japan mean
399 male/female smoking=26.8%, Table 4 versus mean male/female smoking worldwide=20.5%)
400 and SBP (Japan mean male/female SBP=137.6 mm/Hg, Table 4 versus mean male/female SBP
401 worldwide=133.9 mm/Hg, Table 1) but the lowest rate of CVD (mean CVD=169).

402

403 Calcium is essential to cardiovascular function. Calcium's negative correlation with CVD ($r=-$
404 0.177 , 95% CI -0.031 to -0.155 , $p<0.0033$, Table 1) might have been expected.

405

406 The positive correlation of physical activity with CVD was surprising (Table 1). However, (1)
407 countries with more CVD reducing FSVV also had less physical activity (FSVV versus physical
408 activity: $r=-0.366$, 95% CI: -0.385 to -0.347 , $p<0.0001$), (2) females had less physical activity
409 than males (mean physical activity males=5061 METs/week, mean physical activity
410 females=4356 METs/week), along with less CVD (mean CVD males=656.2, mean CVD
411 females=428.6), and (3) males smoked tobacco more than females (mean smoking (0-1)
412 males=0.339 or 33.9%, mean smoking (0-1) females=0.070 or 7%). When FSVV, sex, and
413 smoking were held constant, physical activity correlated negatively with CVD worldwide ($r=-$
414 0.126 , 95% CI -0.148 to -0.104 , $p<0.0001$).

415

416 The moderately strong positive correlation of child ≤ 5 years old severe underweight (>2 SD
417 below the mean for height) with CVD worldwide ($r=0.306$, 95% CI 0.285 to 0.325 , $p<0.0001$,

418 Table 1) suggests a relationship of infant/child malnutrition with later CVD. Babies surviving the
419 so called “Dutch famine” toward the end of the second world war (1944-45) have been shown to
420 have higher subsequent heart disease than earlier or later cohorts in Holland.⁴⁰ The worldwide
421 average rate of severely underweight babies and children from 1990 – 2017 was 18.5% (Table
422 1), suggesting that in utero and early infancy severe malnutrition may subsequently contribute
423 substantially to CVD, especially in developing countries.

424
425 Prematurely stopping breast feeding positively correlated with CVD in the countries with animal
426 food plus added fatty acids ≥ 567.3 KC/d ($r=0.268$ 95% CI: 0.208 to 0.325, $p=0.0027$, Table 5).
427 In those countries, prematurely stopping breast feeding was quite common relative to developing
428 countries (range (0-1): 0.129 to 0.268, mean=0.196). A review of observational studies, in
429 developed countries, of breast feeding related to metabolic risk factors for CVD suggested that
430 breast feeding was associated with increased insulin sensitivity and decreased systolic blood
431 pressure in later life. Breast feeding also has metabolic benefits for the mother.⁴¹

432
433 According to The World Health Organisation, ambient air pollution (particulate
434 matter ≤ 2.5 micrometers diameter (PM_{2.5})) causes cardiovascular and respiratory diseases and
435 cancers.⁴² The WHO considers ≥ 10 $\mu\text{g}/\text{m}^3$ of PM_{2.5} particles a health hazard. In this analysis,
436 the ambient air pollution (PM_{2.5}) in the countries with FSVV ≥ 567.3 KC/d averaged 12.7
437 $\mu\text{g}/\text{m}^3$ and mean CVD=273.7 from 1990 to 2017 (Table 5). Worldwide, comparable numbers
438 were mean CVD=543.7 and air pollution (PM_{2.5}) mean=44.7 $\mu\text{g}/\text{m}^3$.

439
440
441 These IHME GBD data support the link of smoking tobacco to CVD ($r=0.298$, 95% CI
442 0.278 to 0.318, $p<0.0001$, Table 1). However, given the multiple dietary and other

443 contributors, the CVD population attributable risk for smoking is probably far below
444 the World Health Organization estimate that tobacco accounts for 20% of coronary
445 artery disease mortality.⁴³ The mean incidence of smoking worldwide=20.5% (Table
446 1). The mean incidence in the 34 countries with the lowest CVD=23.3% (n=974
447 cohorts). Smoking is clearly a major risk factor for CVD, but these data suggest that
448 diet is more influential in population attributable risk for CVD.

449

450 The positive correlation of blood lead levels with CVD worldwide (r=0.180, 95% CI 0.159 to
451 0.201, p<0.0001, Table 1) is consistent with reports that lead toxicity leads to hypertension.⁴⁴
452 Also, environmental lead exposure has been linked with all-cause mortality,
453 cardiovascular disease mortality, and ischaemic heart disease mortality in the US.⁴⁵

454

455 This analysis showed that kidney disease correlated positively with CVD (r=0.194, 95% CI
456 0.173 to 0.215, p<0.0001, Table 1). A systematic GBD review of kidney disease revealed that
457 chronic kidney disease resulted in 1.2 million deaths in 2017, of which a large portion were from
458 CVD.⁴⁶ Other CVD risk factors may also lead to kidney disease (e.g., systolic hypertension,
459 types 1 and 2 diabetes).

460

461 Influential Stanford University meta researcher, Dr. John Ioannidis, called for radical reform of
462 all nutritional epidemiology methodologies used to influence food/agricultural policies and to
463 produce dietary guidelines for clinicians and the public.⁴⁷ Currently, no methodology for relating
464 cardiovascular disease events to food intake and other risk factors has been generally accepted as
465 rigorous, replicable, and scientifically valid. This study analysing worldwide data for dietary and

466 other risk factors for cardiovascular disease attempts to answer Dr. Ioannidis' call for a more
467 rigorous and reliable nutritional epidemiology methodology to base public health policies and
468 individual dietary guidance.

469

470 **Limitations**

471 Our study was subject to all the limitations discussed in previous GBD publications.^{48,49} These
472 included gaps, biases, and inconsistencies in data sources as well as limitations in the methods of
473 data processing and estimation. Having comprehensive data on dietary inputs is key to more
474 accurate and reliable analyses. The GBD data on animal foods, plant foods, alcohol, sugary
475 beverages, and fatty acids were not comprehensive and comprised only 1191.4 KC/d per person
476 on average worldwide. Subnational data on all risk factors were available on only four countries.
477 Because the data formatting and statistical methodology were new, this was necessarily a post
478 hoc analysis and no pre-analysis protocol was possible. This GBD data analysis should be
479 repeated with the most recently released GBD 2019 data when it becomes available to volunteer
480 collaborators.

481

482 **Generalisability**

483 This new methodology presented for probing the GBD raw data to find correlations between
484 dietary and other risk factors and health outcomes (e.g., CVD) can be applied to any of the risk
485 factors and health outcomes available with the new IHME GBD 2019 data.

486

487 **Conclusion**

488 The lipid hypothesis (e.g., SFA from animal foods causing CVD) may well explain the strong
489 positive correlation of FSVV with CVD in high FSVV cohorts but not worldwide. Global data
490 analysis supports the fat-soluble vitamin hypothesis, because FSVV is negatively correlated with
491 CVD worldwide. Defining the optimal FSVV that will reduce CVD risk while not increasing
492 other diseases (e.g., cancers and obesity) will require more research. Supplements of fat-soluble
493 vitamins to reduce the FSVV required to minimise CVD should be studied, especially in
494 developing countries with less access to animal foods. Reducing FSVV KC/d would also
495 decrease the environmental impacts of animal foods. The findings for the non-dietary risk factors
496 are all consistent with the medical literature except for sodium's negative correlation with CVD.

497
498 This methodology of analysing IHME GBD data should augment systematic literature reviews in
499 developing food and other risk factor policy and education strategies for forming policy
500 recommendations, clinical practice guidelines, and public health recommendations. GBD data
501 analysis can bring more rigor, precision, and consensus to the field of population health,
502 especially in the areas of dietary risk factors.

503

504

505 **Table 1. Dietary and other risks related to CVD worldwide (n=7846 cohorts)**
506

CVD and CVD risk factors	Mean	SD	Min	Max	r	95% CI low	95% CI high	p
CVD/100k/year ages 15-69	543.66	288.01	73.47	1844				
CVD/100k/year ages 15-69 mean m/f	543.69	246.13	135.46	1727	0.855	0.849	0.860	<.0001
LDL cholesterol mmol/L	2.35	0.40	1.27	3.25	-0.279	-0.299	-0.258	<.0001
Fat-soluble vitamin variable (FSVV)	285.36	193.31	58.78	932.18	-0.329	-0.349	-0.309	<.0001
Processed meat KC/d	5.33	9.72	0.20	68.77	-0.204	-0.226	-0.183	<.0001
Red meat KC/d	50.27	45.13	3.21	235.95	-0.232	-0.253	-0.211	<.0001
Fish KC/d	9.99	36.52	0.40	370.36	-0.203	-0.224	-0.181	<.0001
Milk KC/d	25.04	27.05	1.06	146.82	-0.192	-0.214	-0.171	<.0001
Poultry KC/d available	44.32	50.08	1.06	411.87	-0.289	-0.309	-0.268	<.0001
Eggs KC/d available	19.36	14.71	0.79	69.64	-0.390	-0.408	-0.371	<.0001
Added Saturated fatty acids KC/d	87.67	29.41	32.56	221.29	-0.239	-0.260	-0.219	<.0001
Added PUFAs KC/d	37.30	33.78	1.35	175.40	-0.316	-0.336	-0.296	<.0001
Added Trans fatty acids KC/d	6.09	6.28	0.91	35.77	-0.104	-0.126	-0.082	<.0001
Alcohol KC/d	81.03	57.33	4.25	429.81	-0.061	-0.083	-0.039	<.0001
Sugary beverages KC/d	298.36	152.38	72.91	1472.00	0.113	0.091	0.135	<.0001
Potatoes KC/d available	84.04	74.60	3.07	533.88	0.050	0.028	0.073	<.0001
Corn KC/d available	34.72	48.28	0.16	305.17	-0.062	-0.084	-0.040	<.0001
Fruits KC/d	40.21	22.50	3.58	161.39	-0.355	-0.374	-0.336	<.0001
Vegetables KC/d	79.76	43.12	9.48	304.17	-0.107	-0.128	-0.085	<.0001
Nuts and seeds KC/d	8.41	8.36	0.05	102.99	-0.277	-0.297	-0.256	<.0001
Whole grains KC/d	55.65	30.93	1.14	235.10	-0.194	-0.216	-0.173	<.0001
Legumes KC/d	51.74	32.23	0.51	194.70	-0.024	-0.046	-0.002	0.0319
Rice KC/d available	141.86	116.34	1.42	461.80	0.007	-0.015	0.029	0.5417
Sweet potatoes KC/d available	22.76	35.95	0.02	364.74	-0.167	-0.189	-0.146	<.0001
Total KC/d available	2574	418	1579	3898	-0.203	-0.224	-0.181	<.0001
Vit A deficiency children/100k/yr	23205	10939	1267	50969	0.210	0.189	0.231	<.0001
Sodium g/d	4.45	2.34	1.33	9.21	-0.214	-0.235	-0.193	<.0001
Calcium g/d	0.301	0.179	0.081	1.044	-0.169	-0.191	-0.148	<.0001
Dietary fiber g/d	9.21	3.15	2.72	22.68	0.019	-0.003	0.041	0.0932
Physical activity METs	4714	1368	1609	7669	0.160	0.139	0.182	<.0001
Child underweight >2SD	0.186	0.171	0.004	0.535	0.302	0.282	0.322	<.0001
Stop breast feeding <6 months	0.119	0.055	0.016	0.242	-0.302	-0.322	-0.282	<.0001
Ambient pollution PM_{0.25}	44.73	26.46	4.38	95.54	0.153	0.131	0.174	<.0001
Smoking rate (0-1)	0.205	0.176	0.003	0.640	0.297	0.277	0.317	<.0001
Secondhand smoking (0-1)	0.376	0.155	0.164	0.796	-0.225	-0.246	-0.204	<.0001
Sublingual tobacco rate (0-1)	0.068	0.095	0.001	0.419	0.284	0.264	0.304	<.0001
Blood lead level mcg/dl	5.01	1.01	1.22	8.37	0.180	0.159	0.201	<.0001
Household air pollution (0-1)	0.482	0.325	0.000	0.996	0.179	0.158	0.201	<.0001
Kidney disease stage III (0-1)	0.056	0.028	0.015	0.154	0.194	0.173	0.215	<.0001
Type 1 DM early deaths	10.37	9.39	0.55	112.49	0.340	0.320	0.359	<.0001
Type 2 DM early deaths	17.50	15.65	0.63	269.67	0.227	0.205	0.247	<.0001
BMI kg/M²	21.77	2.29	17.95	29.39	-0.240	-0.261	-0.219	<.0001
Fasting plasma glucose mmol/L	4.30	0.35	3.32	5.58	-0.178	-0.200	-0.157	<.0001
Systolic BP mm Hg	133.91	4.32	123.41	147.89	0.195	0.174	0.216	<.0001
Socio-demographic index (0-1)	0.543	0.174	0.112	0.896	-0.337	-0.357	-0.317	<.0001
Sex male 1 and female 2	1.50	0.50	1.00	2.00	-0.395	-0.414	-0.376	<.0001

507 **Table 2. CVD lowest and highest 1000 cohorts (≈1 billion people)**

CVD and risk factors	CVD lowest ≈1 billion people (n=1000 cohorts)				CVD highest ≈1 billion people (n=1000 cohorts)			
	Mean	SD	Min	Max	Mean	SD	Min	Max
Cardiovascular Disease deaths/100k/year	227.81	95.25	73.47	422.36	1045	356.90	430.20	1844
CVD male/female mean	227.81	42.52	135.46	292.97	1045	200.47	802.24	1727
LDL cholesterol mmol/L	2.808	0.256	1.598	3.247	2.376	0.380	1.35	3.20
Fat-soluble vitamin variable (FSVV)	531.4	180.20	143.63	912.69	235.66	99.68	80.53	503.98
Processed meat KC/d	15.30	12.20	0.61	61.09	3.70	4.95	0.22	18.12
Red meat KC/d	90.72	48.06	12.03	235.95	36.82	29.40	7.07	172.00
Fish KC/d	49.54	92.63	2.85	370.36	4.56	2.69	0.78	12.97
Milk KC/d	55.64	35.39	7.70	146.82	25.61	16.78	1.06	75.87
Poultry KC/d available	90.44	47.27	4.74	240.56	30.23	22.39	2.78	100.04
Eggs KC/d available	36.63	11.25	4.77	69.64	14.73	13.63	1.51	46.81
Added Saturated fatty acids KC/d	113.40	36.53	59.52	221.29	87.22	24.03	33.03	205.85
Added PUFAs KC/d	69.80	35.78	15.77	175.40	25.48	14.54	2.73	84.90
Added Trans fatty acids KC/d	9.91	9.25	1.65	34.90	7.31	8.62	1.21	35.77
Alcohol KC/d	119.72	66.67	4.25	296.70	45.83	46.24	5.77	340.37
Sugary beverages KC/d	320.29	251.94	72.91	1472.00	303.30	63.68	180.80	685.42
Potatoes KC/d available	81.34	51.14	9.50	177.30	98.34	96.77	3.94	533.88
Corn KC/d available	48.19	75.26	1.79	287.14	31.77	37.30	0.20	305.17
Fruits KC/d	64.84	16.49	23.05	128.61	31.23	13.93	3.58	70.11
Vegetables KC/d	108.02	44.60	9.48	214.26	83.83	56.67	14.43	198.51
Nuts and seeds KC/d	15.90	10.50	0.66	39.80	4.81	2.91	0.05	17.91
Whole grains KC/d	64.71	38.62	1.61	173.46	28.30	33.01	1.14	156.75
Legumes KC/d	47.88	25.99	2.95	133.26	31.55	18.93	0.51	103.17
Rice KC/d available	78.10	97.95	7.58	349.08	75.93	107.38	1.42	461.80
Sweet potatoes KC/d available	3.92	5.14	0.04	27.51	5.84	20.20	0.02	364.74
Total KC/d available	2972	409	1948	3572	2627	409	1579	3254
Vit A deficiency children/100k/yr	14181	8723	1400	44100	20559	11395	1722	50969
Sodium g/d	3.92	1.22	1.33	6.70	3.30	0.76	1.33	5.96
Calcium g/d	0.506	0.189	0.183	1.044	0.321	0.150	0.089	0.792
Dietary fiber g/d	10.58	2.90	5.15	17.95	9.53	3.32	3.87	18.83
Physical activity METs	3802	1164	2162	7607	4273	1497	1838	7607
Child underweight >2SD	0.038	0.043	0.004	0.242	0.186	0.141	0.011	0.411
Stop breast feeding <6 mo	0.176	0.032	0.071	0.218	0.116	0.044	0.036	0.208
Ambient pollution PM_{0.25}	17.60	8.27	4.38	38.42	40.81	22.19	7.90	77.69
Smoking rate (0-1)	0.217	0.121	0.012	0.448	0.212	0.190	0.005	0.627
Secondhand smoking (0-1)	0.328	0.097	0.164	0.569	0.397	0.158	0.164	0.780
Sublingual tobacco rate (0-1)	0.010	0.015	0.001	0.111	0.060	0.072	0.001	0.238
Blood lead level mcg/dl	4.08	1.00	1.22	6.85	4.74	1.28	1.92	8.37
Household air pollution (0-1)	0.103	0.182	0.001	0.839	0.404	0.353	0.002	0.993
Kidney disease stage III (0-1)	0.042	0.020	0.015	0.111	0.078	0.024	0.035	0.139
Type 1 DM early deaths	4.79	3.88	0.59	20.65	16.38	15.31	2.62	112.49
Type 2 DM early deaths	15.69	18.23	0.75	87.92	23.65	24.88	0.89	269.67
BMI kg/M²	23.74	1.60	19.61	27.06	22.46	2.15	17.95	26.08
Fasting plasma glucose mmol/L	4.56	0.25	3.54	5.12	4.28	0.42	3.38	5.18
Systolic BP mm Hg	133.26	4.41	123.41	142.15	136.86	4.39	124.59	147.89
Socio-demographic index (0-1)	0.757	0.125	0.351	0.896	0.497	0.183	0.186	0.824
Sex male 1 and female 2	1.50	0.50	1.00	2.00	1.50	0.50	1.00	2.00

508 **Table 3. CVD related to fat-soluble vitamin related risk factors in low CVD countries**

CVD lowest Countries (n=1000 cohorts), Table 3	n cohorts	CVD ascending order	FSVV	Processed meat	Red meat	Fish	Milk	Poultry	Eggs	Added SFA +PUFA +TFA
Japan	158	169.19	618.69	19.19	58.72	260.54	29.04	63.93	52.23	135.04
France	64	174.00	644.78	13.59	135.07	11.17	95.75	99.86	43.30	246.04
Switzerland	8	175.04	558.41	11.50	129.01	6.75	110.90	55.57	31.20	213.47
Andorra	2	185.55	763.18	16.58	150.84	16.44	99.23	189.92	47.55	242.62
Peru	32	197.74	183.12	1.01	16.92	3.82	15.34	35.04	12.03	98.95
Spain	46	206.25	597.93	11.65	139.92	10.28	82.99	113.88	43.35	195.86
Italy	60	206.44	587.57	15.78	126.36	9.15	89.54	84.16	36.39	226.20
Iceland	2	206.51	609.62	11.97	112.73	11.67	85.37	63.57	29.51	294.81
Australia	24	208.03	698.26	9.79	164.14	14.15	97.05	153.33	24.92	234.89
Canada	36	222.11	624.98	25.31	126.28	18.48	76.13	147.46	34.94	196.39
Israel	8	228.32	662.00	5.95	59.50	15.35	68.79	240.56	40.54	231.30
South Korea	50	232.63	357.23	5.97	82.88	5.96	15.72	43.10	26.89	176.71
Belgium	12	235.98	636.39	12.28	122.36	11.19	93.44	85.00	33.28	278.86
Netherlands	18	236.61	629.56	15.72	133.06	8.66	114.16	72.70	41.67	243.59
Taiwan	24	237.37	587.36	3.01	106.58	9.15	15.95	132.38	34.87	285.41
Mexico	108	237.55	413.25	11.29	63.03	8.69	34.29	85.85	39.92	170.19
Panama	4	244.31	383.83	2.75	61.32	9.44	20.72	95.43	12.96	181.23
Sweden	10	247.21	563.83	29.31	119.77	11.80	124.13	45.42	35.04	198.37
New Zealand non Mauri	4	247.32	699.81	9.31	158.86	11.56	88.74	128.14	40.24	262.95
Norway	32	248.72	605.30	48.14	109.37	10.10	100.96	41.65	31.52	263.56
England	20	253.09	534.56	19.21	96.29	10.70	87.80	89.30	32.90	198.36
Costa Rica	4	260.73	408.42	2.63	51.74	8.12	46.55	78.05	28.17	193.14
Luxembourg	2	262.53	578.00	14.65	163.17	11.79	91.99	71.48	27.60	197.32
Chile	18	267.50	404.12	19.11	90.33	9.65	31.93	97.29	19.70	136.10
Guatemala	16	269.85	231.05	1.89	20.05	5.28	13.32	53.94	30.46	106.12
Kenya	12	270.04	150.04	1.41	25.83	3.09	18.89	4.74	4.77	91.31
Ecuador	16	270.64	375.35	6.87	56.88	7.34	35.51	59.92	14.66	194.16
USA	94	274.00	825.54	36.45	136.35	15.79	90.90	190.90	41.10	314.05
Denmark	6	275.10	600.48	14.46	137.75	13.38	98.01	74.42	45.96	216.51
Austria	8	277.67	621.00	8.95	194.65	9.26	98.68	70.00	39.96	199.50
Portugal	10	278.50	524.81	5.16	124.77	8.77	79.43	94.26	24.18	188.25
Nicaragua	6	282.04	214.24	1.52	14.93	4.07	20.66	41.76	17.41	113.90
Tehran (Iran)	16	283.29	299.65	1.23	22.63	5.36	19.23	65.90	18.89	166.41
Thailand	70	289.91	247.43	0.70	32.01	6.95	7.85	57.07	31.10	111.75
Total cohorts	1000									

509

510

511 **Table 4. Representative examples of low CVD countries (n=1000 cohorts) including all risk**
 512 **factors**

CVD and CVD risk factors	Japan	France	Peru	Mexico	Panama	Guatemala	Ecuador
n cohorts	158	64	32	108	4	16	16
CVD/100k/year ages 15-69	169.19	174.00	197.74	237.55	244.31	269.85	270.64
Fat-soluble vitamin variable	618.69	644.78	183.12	413.25	383.83	231.05	375.35
LDL cholesterol mmol/L	2.81	3.08	2.37	2.59	2.61	2.20	2.46
Processed meat KC/d	19.19	13.59	1.01	11.29	2.75	1.89	6.87
Red meat KC/d	58.72	135.07	16.92	63.03	61.32	20.05	56.88
Fish KC/d	260.54	11.17	3.82	8.69	9.44	5.28	7.34
Milk KC/d	29.04	95.75	15.34	34.29	20.72	13.32	35.51
Poultry KC/d available	63.93	99.86	35.04	85.85	95.43	53.94	59.92
Eggs KC/d available	52.23	43.30	12.03	39.92	12.96	30.46	14.66
Added Saturated fatty acids KC/d	77.73	172.79	68.34	89.13	101.32	60.62	133.54
Added PUFAs KC/d	53.78	67.38	24.47	52.14	72.29	41.90	51.69
Added Trans fatty acids KC/d	3.54	5.88	6.13	28.92	7.62	3.60	8.93
Alcohol KC/d	183.16	118.64	55.79	58.39	27.44	28.79	59.77
Sugary beverages KC/d	94.78	323.88	284.76	847.81	921.54	964.08	283.57
Potatoes KC/d available	42.29	126.40	142.55	25.79	32.01	16.68	67.56
Corn KC/d available	27.58	23.85	33.54	242.41	50.86	206.19	11.76
Fruits KC/d	44.43	59.56	52.27	65.68	52.92	39.61	107.07
Vegetables KC/d	149.32	101.07	46.17	60.72	27.81	54.98	31.79
Nuts and seeds KC/d	9.26	16.94	1.02	6.27	1.92	12.72	0.68
Whole grains KC/d	76.05	16.16	58.94	142.06	83.46	68.32	43.78
Legumes KC/d	71.84	17.07	45.78	76.99	38.35	73.84	21.99
Rice KC/d available	124.52	12.09	93.09	14.07	141.66	13.46	118.02
Sweet potatoes KC/d available	12.09	0.04	7.94	0.69	8.67	1.71	0.49
Total KC/d available	2590	3406	1948	3015	2288	2330	2273
Vit A deficiency children/100k/yr	8151	1643	19372	23939	11463	17947	20185
Sodium g/d	6.01	3.21	3.14	2.62	2.97	1.83	3.16
Calcium g/d	0.425	0.707	0.299	0.370	0.293	0.220	0.314
Dietary fiber g/d	13.43	8.68	9.44	15.51	5.90	12.54	6.25
Physical activity METs	3460	2795	3774	3833	4935	6142	3740
Child underweight >2SD	0.045	0.012	0.069	0.050	0.042	0.193	0.096
Stop breast feeding <6 months	0.171	0.208	0.108	0.171	0.140	0.087	0.130
Ambient pollution PM_{0.25}	13.10	13.87	28.99	24.28	13.24	28.61	17.86
Smoking rate (0-1)	0.268	0.289	0.075	0.149	0.073	0.077	0.080
Secondhand smoking (0-1)	0.353	0.320	0.238	0.344	0.178	0.224	0.206
Sublingual tobacco rate (0-1)	0.012	0.003	0.004	0.002	0.002	0.001	0.004
Blood lead level mcg/dl	2.65	3.86	5.17	5.34	4.80	5.89	4.51
Household air pollution (0-1)	0.002	0.010	0.454	0.213	0.193	0.627	0.080
Kidney disease stage III (0-1)	0.038	0.028	0.050	0.078	0.068	0.075	0.055
Type 1 DM early deaths	1.25	2.91	4.84	12.64	7.71	12.03	6.92
Type 2 DM early deaths	2.03	3.70	11.37	60.97	18.07	40.38	27.44
BMI kg/M²	21.89	23.47	23.29	24.82	22.98	21.97	25.04
Fasting plasma glucose mmol/L	4.77	4.46	4.01	4.53	4.31	4.12	4.26
Systolic BP mm Hg	137.56	135.11	125.19	130.31	133.66	131.15	126.85
Socio-demographic index	0.828	0.822	0.590	0.608	0.644	0.431	0.575
Likely mechanism of low CVD	FSVV Plants	FSVV	Low smoking metabolic	FSVV Plants	FSVV PA Low smoking	PA Low smoking	FSVV Low smoking

513


514

515 **Table 5. CVD and risk factors for countries with FSVV ≥ 567.27 KC/d (n=974 cohorts)**

CVD and CVD risk factors	Mean	SD	Min	Max	r	95% CI low	95% CI high	p
Cardiovascular deaths/100k/year ages 15-69	273.72	143.95	73.47	913.18				
LDL cholesterol mmol/L	2.91	0.14	2.36	3.20	-0.254	-0.312	-0.194	<.0001
Fat-soluble vitamin variable	692.58	111.88	527.67	932.18	0.523	0.476	0.567	<.0001
Processed meat KC/d	25.01	15.30	2.16	68.77	0.459	0.408	0.507	<.0001
Red meat KC/d	122.16	41.41	43.65	235.95	0.655	0.618	0.690	<.0001
Fish KC/d	49.08	89.24	7.60	370.36	-0.259	-0.317	-0.199	<.0001
Milk KC/d	78.58	26.14	14.60	146.82	0.185	0.123	0.245	<.0001
Poultry KC/d available	129.97	60.21	41.65	411.87	0.366	0.311	0.419	<.0001
Eggs KC/d available	40.80	7.25	14.59	69.64	-0.242	-0.301	-0.182	<.0001
Saturated fatty acids KC/d	299.88	66.83	129.39	481.07	0.193	0.132	0.253	<.0001
PUFAs KC/d	211.86	83.06	80.53	381.31	0.382	0.327	0.435	<.0001
Trans fatty acids KC/d	25.17	17.82	4.23	66.89	0.224	0.163	0.283	<.0001
Alcohol KC/d	155.02	65.23	11.92	429.81	0.475	0.425	0.522	<.0001
Sugary beverages KC/d	231.66	121.92	72.91	769.89	0.332	0.274	0.386	<.0001
Potatoes KC/d available	106.39	40.47	9.50	224.86	0.109	0.046	0.170	0.00
Corn KC/d available	19.45	9.41	1.79	47.39	0.086	0.024	0.148	0.01
Fruits KC/d	66.91	15.93	34.83	161.39	-0.014	-0.077	0.049	0.66
Vegetables KC/d	117.42	34.24	42.27	304.17	-0.127	-0.188	-0.064	<.0001
Nuts and seeds KC/d	21.98	8.91	0.85	102.99	0.177	0.115	0.237	<.0001
Whole grains KC/d	52.11	20.93	1.61	92.45	0.121	0.059	0.183	0.00
Legumes KC/d	40.76	25.29	2.95	133.26	0.040	-0.023	0.102	0.21
Rice KC/d available	38.82	46.75	6.50	179.63	-0.138	-0.199	-0.076	<.0001
Sweet potatoes KC/d available	3.63	3.99	0.04	17.63	-0.128	-0.189	-0.066	<.0001
Total KC/d available	3219	292	2516	3898	0.249	0.189	0.307	<.0001
Vit A deficiency children/100k/yr	9316	6877	1400	28081	-0.105	-0.166	-0.042	0.00
Sodium g/d	3.98	0.96	2.22	6.70	-0.040	-0.102	0.023	0.21
Calcium g/d	0.645	0.129	0.353	1.044	0.396	0.342	0.448	<.0001
Dietary fiber g/d	10.62	1.75	6.30	18.15	0.241	0.181	0.299	<.0001
Physical activity METs	3523	765	1781	5494	0.578	0.535	0.618	<.0001
Child underweight >2SD	0.015	0.013	0.004	0.058	-0.197	-0.257	-0.136	<.0001
Stop breast feeding <6 months	0.196	0.017	0.129	0.219	0.268	0.208	0.325	<.0001
Ambient pollution PM _{0.25}	12.67	7.13	4.38	87.22	0.005	-0.058	0.068	0.87
Smoking rate (0-1)	0.233	0.084	0.021	0.444	0.233	0.172	0.291	<.0001
Secondhand smoking (0-1)	0.309	0.070	0.201	0.586	-0.306	-0.362	-0.248	<.0001
Sublingual tobacco rate (0-1)	0.013	0.020	0.001	0.125	0.579	0.536	0.620	<.0001
Blood lead level mcg/dl	3.93	0.77	1.22	5.72	0.451	0.400	0.500	<.0001
Household air pollution (0-1)	0.012	0.026	0.000	0.201	-0.011	-0.073	0.052	0.74
Kidney disease stage III (0-1)	0.036	0.012	0.016	0.109	-0.028	-0.090	0.035	0.39
Type 1 DM early deaths	3.93	2.67	0.55	15.97	0.573	0.529	0.613	<.0001
Type 2 DM early deaths	9.54	7.52	0.75	54.22	0.622	0.582	0.659	<.0001
BMI kg/M ²	24.87	1.78	21.40	29.39	0.484	0.434	0.530	<.0001
Fasting plasma glucose mmol/L	4.73	0.23	3.84	5.58	0.091	0.028	0.153	0.00
Systolic BP mm Hg	133.639	4.362	126.863	142.147	-0.148	-0.209	-0.086	<.0001
Socio-demographic index (0-1)	0.838	0.053	0.592	0.896	-0.052	-0.114	0.011	0.11
Sex male 1 and female 2	1.50	0.50	1.00	2.00	-0.745	-0.772	-0.716	<.0001

516
517

518 **Figure 1. LDLc versus CVD scatter plot**



519

520 **Supplementary Table 1. Definitions of GBD risk factors and covariates related to CVD**

Variables	Definition
Alcohol	Any alcohol consumption (g/day)
Ambient particulate matter pollution	Annual average daily exposure to outdoor air concentrations of particulate matter with an aerodynamic diameter of $\leq 2.5 \mu\text{g}/\text{m}^3$ (PM _{2.5})
Body-mass index	Body mass index (BMI) (kg/m ²)—the dependent variable of interest
Chewing tobacco	Current use of any chewing tobacco product
Child underweight	Proportion of children – 3 SD to – 2 SD of the WHO 2006 standard weight-for-age curve (0-1)
Corn	Corn availability per capita (g/day), a covariate
Discontinued breast feeding	Proportion of children aged 6-23 months who do not receive any breast milk
Eggs	Eggs availability per capita (g/day) a covariate
Fasting plasma glucose	Fasting plasma glucose (mmol/L)
Fish	This variable expressed in g/day was derived by determining the weight of fish in g corresponding to 1 g of omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) by averaging the fish g per 1 g of omega-3 fatty acids 20 species of fish= 117.04 g/day fish/1 g/day omega-3 fatty acids (Supplementary Table 3)
Fruits	Consumption of fruits (includes fresh, frozen, cooked, canned, or dried fruit but excludes fruit juices and salted or pickled fruits) (g/day)
Household air pollution from solid fuels	Individual exposure to PM _{2.5} due to use of solid cooking fuel
Kidney function impaired	Proportion of the population with ACR >30 mg/g or GFR <60 mL/min/1.73 m ² , excluding end-stage renal disease
Kilocalories available /day	The mean number of kilocalories per capita available per day to people in each location (kcal/day available), a covariate
LDL cholesterol	Serum low-density lipoprotein cholesterol (mmol/L)
Lead exposure	Blood lead levels in $\mu\text{g}/\text{dL}$ of blood, bone lead levels in $\mu\text{g}/\text{g}$ of bone
Legumes	Consumption of beans, lentils, pulses (g/day)
Milk	Consumption of milk including non-fat, low-fat, and full-fat milk but excluding soy milk and other plant derivatives (g/day)
Nuts and seeds	Consumption of nuts and seeds (g/day)
Physical activity	Average weekly physical activity at work, home, transport-related and recreational measured by MET min per week. Less than 3000 METs per week constitutes low physical activity.
Poultry	Poultry availability per capita (g/day), a covariate
Potatoes	Potatoes availability per capita (g/day), a covariate
Processed meat	Consumption of any processed meat (includes meat preserved by smoking, curing, salting, or addition of chemical preservatives, including bacon, salami, sausages, or deli or luncheon meats like ham, turkey, and pastrami) (g/day)
Red meat	Consumption of red meat (includes beef, pork, lamb, and goat but excludes poultry, fish, eggs, and all processed meats) (g/day)
Rice	Rice availability per capita (g/day), a covariate
Seafood omega-3 fatty acids	Seafood omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) in tablet or fish form (g/day)
Second-hand smoke	Average daily exposure to air particulate matter from second-hand smoke with an aerodynamic diameter smaller than 2.5 μg , measured in $\mu\text{g}/\text{m}^3$, among non-smokers
Smoking	Prevalence of current use of any smoked tobacco product and prevalence of former use of any smoked tobacco product; among current smokers, cigarette equivalents smoked per smoker per day and cumulative pack-years of exposure; among former smokers, number of years since quitting
Socio-demographic index	SDI is a composite indicator of development status that was originally constructed for GBD 2015 and is derived from components that correlate strongly with health outcomes.

	It is the geometric mean for indices of the total fertility rate among women younger than 25 years, mean education for those aged 15 years or older, and lag-distributed income per capita. The resulting metric ranges from 0 to 1, with higher values corresponding to higher levels of development.
Sugar-sweetened beverages	Consumption of any beverage with ≥ 50 calories of sugar per one-cup serving, including carbonated beverages, sodas, energy drinks, fruit drinks but excluding 100% fruit and vegetable juices (g/day)
Sweet potatoes	Sweet potato availability per capita (g/day), a covariate
Systolic blood pressure	Systolic blood pressure (mm Hg)
Total sugar	Total sugar availability per capita (g/day), a covariate
Vegetables	Consumption of frozen, cooked, canned, or dried vegetables (including legumes but excluding salted or pickled, juices, nuts and seeds, and starchy vegetables such as potatoes or corn) (g/day)
Vitamin A deficiency	Proportion of children aged 0–5 years with serum retinol concentration $< 0.7 \mu\text{mol/L}$
Whole grains	Consumption of whole grains (bran, germ, and endosperm in their natural proportions) from breakfast cereals, bread, rice, pasta, biscuits, muffins, tortillas, pancakes, and others (g/day)

521

522 **Supplementary Table 2. STROBE 2007 (v4) Statement—Checklist of items that should be**
 523 **included in reports of cohort studies**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10 and Supplementary Table 1
Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-9, Supplementary Tables 2-3
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Ecological data↓	13	(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	9↓
		(b) Indicate number of participants with missing data for each variable of interest	NA

		(c) Summarise follow-up time (e.g., average and total amount)	NA
Outcome data	15	Report numbers of outcome events or summary measures over time	Tables 1-5, 26-30
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15-17, Tables 1-5, 26-30,
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	13-15
Discussion			
Key results	18	Summarize key results with reference to study objectives	18-23
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	24-25
Generalisability	21	Discuss the generalisability (external validity) of the study results	24
Other information			
		Data availability statement	41
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	40

524
525
526
527

↓Global Burden of Disease ecological data on worldwide male and female cohorts from IHME is the data source rather than individual participants

528 **Supplementary Table 3. Omega-3 Fatty Acid g to fish g calculation¶**

Fish	DHA g/3-ounce fish	EPA g/3-ounce fish	Omega-3 Fatty Acids (DHA + EPA) g/3-ounce fish mean	Fish 3 ounces = 85.02 g	Fish (g) per omega-3 Fatty Acids (g)=85.02 / 0.7264
Salmon Atlantic farmed	1.24	0.59			
Salmon Atlantic wild	1.22	0.35			
Herring Atlantic	0.94	0.77			
Sardines canned in tomato sauce drained	0.74	0.45			
Mackerel Atlantic	0.59	0.43			
Salmon pink canned drained	0.63	0.28			
Trout rainbow wild	0.44	0.40			
Oysters eastern wild	0.23	0.30			
Sea bass	0.47	0.18			
Shrimp	0.12	0.12			
Lobster	0.07	0.10			
Tuna light canned in water drained	0.17	0.02			
Tilapia	0.11				
Scallops	0.09	0.06			
Cod Pacific	0.1	0.04			
Tuna yellowfin	0.09	0.01			
Mean DHA and EPA Omega-3 Fatty Acids g/3 ounce fish	0.4531	0.2733			
Calculations total Omega-3 FA g to fish g			0.7264	85.02	117.043

529 ¶ Data on omega-3 fatty acid content of varieties of fish came from the National Institutes of
 530 Health Office of Dietary Supplements (USA)
 531

532

533

534 **Supplementary Table 4. Calculations of KC/d from g/day of animal and plant foods¶**

Foods	Food sub-categories	kcal/serving	g/serving	kcal/g
Milk (2% fat)		122	244	0.5
Fish		218	170	1.28
Eggs		72	50	1.44
Poultry		187	85	2.91
Red meat		247	85	2.91
Processed meat				
	Salami	222	59	3.76
	Pastrami	104	71	1.46
	Ring baloney	86	28	3.07
	Pepperoni	94	100	0.94
Average processed meat		126.5	64.5	1.96
Fruits		97	162	0.60
Vegetables		59	91	0.65
Legumes		249	179	1.39
Nuts		172	28	6.14
Seeds				
	Flax seeds	55	10	5.5
	Chia seeds	58	12	4.83
	Fennel seeds	34.5	10	3.45
	Hemp seeds	55.3	10	5.53
Average of seeds		50.7	10.5	4.83
Average of nuts and seeds		111.4	19.25	5.78
Corn		99	103	0.96
Potatoes		161	173	0.93
Sweet potatoes		115	151	0.76
Rice		205	158	1.3
Whole grains		120	52	2.31

535 ¶ Source: NutritionIX app²⁵

536

537

538 **Acknowledgments**

539• **Authors' contributions:** DKC acts as guarantor; conceived and designed the study, acquired
540 and analysed the data, interpreted the study findings, drafted the manuscript, critically reviewed
541 and edited the manuscript and tables, and approved the final version for publication.

542

543 CW designed software programs in R to format and population weight the data,
544 aided with the SAS statistical analysis, critically reviewed the manuscript, and
545 approved the final version for publication.

546

547 The corresponding author attests that all listed authors meet authorship criteria and that no others
548 meeting the criteria have been omitted.

549

550 **Copyright:** The authors retain the copyright to the paper

551

552 **The Patient and Public Involvement**

553 • When and how were patients/public first involved in the research?

554 IHME acquired, catalogued and extracted information from over 12,000 surveys from
555 government and non-government agencies to compile the GBD database.

556 • How were the research question(s) developed and informed by their priorities,
557 experience, and preferences?

558 The diverse surveys contributing to the GBD database had many different priorities and
559 intentions unrelated to this post hoc analysis. The current analysis research questions have been

560 developed to give researchers, policymakers, and the public the methodological tool to quantify
561 the impacts of dietary and other risk factor patterns.

562 ● How were patients/public involved in

563 (a) the design and conduct of the study?

564 The way patients/public were involved in the collection of the surveys has not been
565 systematically studied and reported on. Patients/public are the intended beneficiaries of
566 this analysis of the GBD data.

567 (b) choice of outcome measures?

568 The outcome measures chosen all relate to human health.

569 (c) recruitment to the study?

570 The recruitment methods vary by the survey.

571 ● How were (or will) patients/ public be involved in choosing the methods and agreeing
572 plans for dissemination of the study results to participants and linked communities?

573 IHME and all the health surveyors that contributed will make these decisions. This analysis of
574 the data will be available to all by open access.

575

576● **Competing interests statement:** Both authors have completed the ICMJE uniform disclosure
577 form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
578 submitted work; no financial relationships with any organisations that might have an interest in
579 the submitted work in the previous three years; no other relationships or activities that could
580 appear to have influenced the submitted work.

581

582 **Transparency declaration:** The manuscript is an honest, accurate, and transparent account of
583 the study being reported. No important aspects of the study have been omitted. Any
584 discrepancies from the study as planned have been explained.

585

586 **Ethics:** Studies based solely on data from IHME GBD database do not need approval from any
587 bioethics committee.

588

589• **Funding:** This research received no grant from any funding agency in the public, commercial or
590 not-for-profit sectors. The Bill and Melinda Gates Foundation funded the acquisition of the data
591 for this analysis by the IHME. The data were provided to the authors as volunteer collaborators
592 with IHME.

593•

594 **Details of the role of the study sponsors:** While IHME GBD faculty and staff by virtue of
595 Gates Foundation grants provided the raw data for this analysis, they did not vet the analysis or
596 sponsor the manuscript.

597

598 **Statement of independence of researchers from funders:** The researchers have received no
599 funding. Gates Foundation funded IHME to collect or analyse the GBD data.

600

601 **Dissemination declaration:** Dissemination of this manuscript to the participants of the more
602 than 12,000 surveys is not possible individually, but the information will become in the public
603 domain.

604

605 **Disclosures:** We thank Scott Glenn and Brent Bell from IHME who supplied us with the GBD
606 risk factor exposure data for the risk factors and for noncommunicable disease death data.

607•

608 **Ethics:** Studies were based solely on data from the IHME GBD database and do not need
609 approval from any bioethics committee.

610

611 **Participant informed consents:** Not applicable.

612

613 **Author access to data:** As volunteer collaborators with the Institute of Health Metrics and
614 Evaluation, we received about 1.4 gigabytes of raw data on noncommunicable disease deaths and
615 32 relevant risk factors.

616

617 **Data sharing statement:** On acceptance for publication by the Lancet, our dataset and SAS
618 codes will be posted on the Mendeley data repository (<https://data.mendeley.com/>).

619

620 **Protocol, submitted as a supplementary file:** Not applicable.

621

622 **STROBE checklist:** Submitted.

623

624 **Patient consent:** Not applicable.

625

626

627 References

- 628 1. Keys A, Menotti A, Karvonen MJ, et al. **The diet and 15-year death rate in the seven**
629 **countries study.** *Am J Epidemiol.* 1986; **124** (6): 903-15.
630 <https://academic.oup.com/aje/article-abstract/124/6/903/174332?redirectedFrom=fulltext>
- 631 2. DuBroff R. **A Reappraisal of the Lipid Hypothesis.** *The American Journal of*
632 *Medicine.* 2018; **131** (9): 993-997. <https://doi.org/10.1016/j.amjmed.2018.04.027>
- 633 3. Teicholz N. **The scientific report guiding the US dietary guidelines: is it scientific?**
634 *BMJ.* 2015; **351**. <http://www.bmj.com/bmj/351/bmj.h4962.full.pdf>
- 635 4. **Outcome of Post-publication review of article by Nina Teicholz.** *BMJ.* 2015; **351:**
636 **h4962.** <https://www.bmj.com/content/351/bmj.h4962/rr-48>
- 637 5. Zile MH. **Vitamin A-not for your eyes only: requirement for heart formation begins**
638 **early in embryogenesis.** *Nutrients.* 2010; **2** (5): 532-50.
- 639 6. Xing X, Tao F. **[Advance of study on vitamin A deficiency and excess associated**
640 **with congenital heart disease].** *Wei Sheng Yan Jiu.* 2008; **37** (6): 754-6.
- 641 7. Saremi A, Arora R. **Vitamin E and cardiovascular disease.** *Am J Ther.* 2010; **17** (3):
642 e56-65.
- 643 8. Beulens JWJ, Booth SL, van den Heuvel EGHM, Stoecklin E, Baka A, Vermeer C. **The**
644 **role of menaquinones (vitamin K2) in human health.** *British Journal of Nutrition.*
645 2013; **110:** 1357–1368. [https://www.cambridge.org/core/journals/british-journal-of-](https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/the-role-of-menaquinones-vitamin-k2-in-human-health/5B9F317B526629D8BA77B6435F1E5509)
646 [nutrition/article/the-role-of-menaquinones-vitamin-k2-in-human-](https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/the-role-of-menaquinones-vitamin-k2-in-human-health/5B9F317B526629D8BA77B6435F1E5509)
647 [health/5B9F317B526629D8BA77B6435F1E5509](https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/the-role-of-menaquinones-vitamin-k2-in-human-health/5B9F317B526629D8BA77B6435F1E5509)
- 648 9. Wang L, Song Y, Manson JE, et al. **Circulating 25-Hydroxy-Vitamin D and Risk of**
649 **Cardiovascular Disease: A Meta-Analysis of Prospective Studies.** *Circulation:*
650 *Cardiovascular Quality and Outcomes.* 2012; **5** (6): 819-829.
651 <http://circoutcomes.ahajournals.org/content/5/6/819.abstract>
- 652 10. Fu X, Harshman SG, Shen X, et al. **Multiple Vitamin K Forms Exist in Dairy Foods.**
653 *Current developments in nutrition.* 2017; **1** (6): e000638-e000638.
654 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998353/>
- 655 11. Walther B, Chollet M. Vitamin K2 - Vital for Health and Wellbeing. In: Gordeladze JO,
656 ed. Menaquinones, Bacteria, and Foods: Vitamin K2 in the Die: IntechOpen, 2017.
- 657 12. Kamao M, Suhara Y, Tsugawa N, et al. **Vitamin K content of foods and dietary**
658 **vitamin K intake in Japanese young women.** *J Nutr Sci Vitaminol (Tokyo).* 2007; **53**
659 (6): 464-70. <https://pubmed.ncbi.nlm.nih.gov/18202532/>
- 660 13. Kaneki M HS, Hosoi T, Fujiwara S, Lyons A, Crean SJ, Ishida N, Nakagawa M, Takechi
661 M, Sano Y, Mizuno Y, Hoshino S, Miyao M, Inoue S, Horiki K, Shiraki M, Ouchi Y,
662 Orimo H. **Japanese fermented soybean food as the major determinant of the large**
663 **geographic difference in circulating levels of vitamin K2: possible implications for**
664 **hip-fracture risk.** *Nutrition.* 2001; **17** (4): 315-21.
665 <https://pubmed.ncbi.nlm.nih.gov/11369171/>
- 666 14. Tamang JP, Cotter PD, Endo A, et al. **Fermented foods in a global age: East meets**
667 **West.** *Comprehensive Reviews in Food Science and Food Safety.* 2020; **19** (1): 184-217.
668 <https://onlinelibrary.wiley.com/doi/full/10.1111/1541-4337.12520>
- 669 15. Joseph M. Fermented Soy Products: A Guide To 12 Traditional Foods. Nutrition
670 Advance 2020; Accessed April 11, 2021.

- 671 16. Global Burden of Disease Study 2017 (GBD 2017) Data Input Sources Tool. Seattle,
672 Washington: Institute of Health Metrics and Evaluation Accessed August 10, 2019.
673 <http://ghdx.healthdata.org/gbd-2017/data-input-sources>
- 674 17. **GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative**
675 **risk assessment of 84 behavioural, environmental and occupational, and metabolic**
676 **risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic**
677 **analysis for the Global Burden of Disease Study 2017: Table of risk factor**
678 **definitions.** *The Lancet*. 2018; **392** (10159): 1923-94.
679 [https://www.thelancet.com/action/showFullTableHTML?isHtml=true&tableId=tbl1&pii=](https://www.thelancet.com/action/showFullTableHTML?isHtml=true&tableId=tbl1&pii=S0140-6736%2818%2932225-6)
680 [S0140-6736%2818%2932225-6](https://www.thelancet.com/action/showFullTableHTML?isHtml=true&tableId=tbl1&pii=S0140-6736%2818%2932225-6)
- 681 18. PROTOCOL FOR THE GLOBAL BURDEN OF DISEASES, INJURIES, AND RISK
682 FACTORS STUDY (GBD) Version 3.0; Issue 26. Seattle, Washington: Institute for
683 Health Metrics and Evaluation Accessed August 2, 2019.
684 http://www.healthdata.org/sites/default/files/files/Projects/GBD/GBD_Protocol.pdf
- 685 19. Naghavi M, Abajobir AA, Abbafati C, et al. **Global, regional, and national age-sex**
686 **specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the**
687 **Global Burden of Disease Study 2016.** *The Lancet*. 2017; **390** (10100): 1151-1210.
688 [https://doi.org/10.1016/S0140-6736\(17\)32152-9](https://doi.org/10.1016/S0140-6736(17)32152-9)
- 689 20. Flaxman AD, Lee YY, Vos T, et al. An Integrative Metaregression Framework for
690 Descriptive Epidemiology. Seattle, WA: University of Washington Press, 2015.
- 691 21. GBD 2017 Risk Factor Collaborators. **Global, regional, and national comparative risk**
692 **assessment of 84 behavioural, environmental and occupational, and metabolic risks**
693 **or clusters of risks for 195 countries and territories, 1990–2017: a systematic**
694 **analysis for the Global Burden of Disease Study 2017.** . *The Lancet*. 2018; **392**
695 (10159): 1923-94. [https://doi.org/10.1016/S0140-6736\(18\)32225-6](https://doi.org/10.1016/S0140-6736(18)32225-6)
- 696 22. Call for Collaborators. . Seattle, Washington: Institute for Health Metrics and Evaluation
697 at the University of Washington 2019; Accessed April 25, 2019.
698 <http://www.healthdata.org/gbd/call-for-collaborators>
- 699 23. Stevens GA, Alkema L, Black PRE, et al. **Guidelines for Accurate and Transparent**
700 **Health Estimates Reporting: the GATHER statement.** *The Lancet*. 2016; **388**
701 (10062): e19-e23. [https://doi.org/10.1016/S0140-6736\(16\)30388-9](https://doi.org/10.1016/S0140-6736(16)30388-9)
- 702 24. Omega 3 Fatty Acids: Fact Sheet for Health Professionals. The Office of Dietary
703 Supplements 2018; Accessed September 1, 2018.
704 <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/>
- 705 25. Nutritionix Track App. Syndigo LLC Accessed April 25, 2019.
706 <https://www.nutritionix.com/>
- 707 26. Ritchie H, Roser M. **Diet Compositions.** *Our World in Data*. 2017.
708 <https://ourworldindata.org/diet-compositions>
- 709 27. Pu J, Romanelli R, Zhao B, et al. **Dyslipidemia in special ethnic populations.**
710 *Cardiology clinics*. 2015; **33** (2): 325-333.
711 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421090/>
- 712 28. Frank ATH, Zhao B, Jose PO, Azar KMJ, Fortmann SP, Palaniappan LP. **Racial/ethnic**
713 **differences in dyslipidemia patterns.** *Circulation*. 2014; **129** (5): 570-579.
714 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212818/>
- 715 29. Mahmood SS, Levy D, Vasan RS, Wang TJ. **The Framingham Heart Study and the**
716 **epidemiology of cardiovascular disease: a historical perspective.** *Lancet (London,*

- 717 *England*). 2014; **383** (9921): 999-1008.
718 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159698/>
719 30. Dehghan M, Mente A, Zhang X, et al. **Associations of fats and carbohydrate intake**
720 **with cardiovascular disease and mortality in 18 countries from five continents**
721 **(PURE): a prospective cohort study.** *The Lancet*. 2017; **390** (10107): 2050-2062.
722 [https://doi.org/10.1016/S0140-6736\(17\)32252-3](https://doi.org/10.1016/S0140-6736(17)32252-3)
723 31. Countries Who Eat The Most Cheese. World Atlas 2021; Accessed March 28, 2021.
724 [https://www.worldatlas.com/articles/countries-who-consume-the-most-](https://www.worldatlas.com/articles/countries-who-consume-the-most-cheese.html#:~:text=The%20top%20cheese%20consumer%20is,kilograms%20of%20cheese%20per%20capita.)
725 [cheese.html#:~:text=The%20top%20cheese%20consumer%20is,kilograms%20of%20cheese%20per%20capita.](https://www.worldatlas.com/articles/countries-who-consume-the-most-cheese.html#:~:text=The%20top%20cheese%20consumer%20is,kilograms%20of%20cheese%20per%20capita.)
726
727 32. Cheese Consumption Per Capita in New Zealand. Czech Republic: Helgi Library,
728 Source: Faostat Accessed April 9, 2021. [https://www.helgilibrary.com/indicators/cheese-](https://www.helgilibrary.com/indicators/cheese-consumption-per-capita/new-zealand/)
729 [consumption-per-capita/new-zealand/](https://www.helgilibrary.com/indicators/cheese-consumption-per-capita/new-zealand/)
730 33. Khalil Z, Alam B, Akbari AR, Sharma H. **The Medical Benefits of Vitamin K(2) on**
731 **Calcium-Related Disorders.** *Nutrients*. 2021; **13** (2): 691.
732 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926526/>
733 34. POTATO PROCESSING AND USES. Lima, Peru: International Potato Center
734 Accessed May 28, 2020. <https://cipotato.org/potato/potato-processing-uses/>
735 35. Juul F, Vaidean G, Lin Y, Deierlein Andrea L, Parekh N. **Ultra-Processed Foods and**
736 **Incident Cardiovascular Disease in the Framingham Offspring Study.** *Journal of the*
737 *American College of Cardiology*. 2021; **77** (12): 1520-1531.
738 <https://doi.org/10.1016/j.jacc.2021.01.047>
739 36. Srour B, Fezeu LK, Kesse-Guyot E, et al. **Ultra-processed food intake and risk of**
740 **cardiovascular disease: prospective cohort study (NutriNet-Santé).** *BMJ*. 2019; **365**:
741 11451. <https://www.bmj.com/content/bmj/365/bmj.11451.full.pdf>
742 37. Monteiro CA, Moubarac JC, Cannon G, Ng SW, Popkin B. **Ultra-processed products**
743 **are becoming dominant in the global food system.** *Obes Rev*. 2013; **14** Suppl 2: 21-8.
744 38. Mozaffarian D, Fahimi S, Singh GM, et al. **Global Sodium Consumption and Death**
745 **from Cardiovascular Causes.** *New England Journal of Medicine*. 2014; **371** (7): 624-
746 634. <https://www.nejm.org/doi/full/10.1056/NEJMoa1304127>
747 39. O'Donnell M, Mente A, Yusuf S. **Sodium Intake and Cardiovascular Health.**
748 *Circulation Research*. 2015; **116** (6): 1046-1057.
749 <https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.116.303771>
750 40. Roseboom T, van der Meulen JHP, Osmond C, et al. **Coronary heart disease after**
751 **prenatal exposure to the Dutch famine, 1944-45.** *Heart*. 2000; **84** (6): 595-598.
752 <https://www.heart.bmj.com/content/84/6/595>
753 41. Dieterich CM, Felice JP, O'Sullivan E, Rasmussen KM. **Breastfeeding and health**
754 **outcomes for the mother-infant dyad.** *Pediatric clinics of North America*. 2013; **60** (1):
755 31-48. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508512/>
756 42. Ambient (outdoor) air pollution. Geneva, Switzerland: World Health Organization 2018;
757 Accessed March 24, 2021. [https://www.who.int/news-room/fact-sheets/detail/ambient-](https://www.who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-and-health)
758 [\(outdoor\)-air-quality-and-health](https://www.who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-and-health)
759 43. Tobacco responsible for 20% of deaths from coronary heart disease Geneva,
760 Switzerland: World Health Organization 2020; Accessed March 2, 2021.
761 [https://www.who.int/news/item/22-09-2020-tobacco-responsible-for-20-of-deaths-from-](https://www.who.int/news/item/22-09-2020-tobacco-responsible-for-20-of-deaths-from-coronary-heart-disease)
762 [coronary-heart-disease](https://www.who.int/news/item/22-09-2020-tobacco-responsible-for-20-of-deaths-from-coronary-heart-disease)

- 763 44. Vaziri ND. **Mechanisms of lead-induced hypertension and cardiovascular disease.**
764 *American Journal of Physiology-Heart and Circulatory Physiology.* 2008; **295** (2):
765 H454-H465. <https://journals.physiology.org/doi/abs/10.1152/ajpheart.00158.2008>
766 45. Lanphear BP, Rauch S, Auinger P, Allen RW, Hornung RW. **Low-level lead exposure**
767 **and mortality in US adults: a population-based cohort study.** *The Lancet Public*
768 *Health.* 2018; **3** (4): e177-e184. [https://doi.org/10.1016/S2468-2667\(18\)30025-2](https://doi.org/10.1016/S2468-2667(18)30025-2)
769 46. Bikbov B, Purcell CA, Levey AS, et al. **Global, regional, and national burden of**
770 **chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of**
771 **Disease Study 2017.** *The Lancet.* 2020; **395** (10225): 709-733.
772 [https://doi.org/10.1016/S0140-6736\(20\)30045-3](https://doi.org/10.1016/S0140-6736(20)30045-3)
773 47. Ioannidis JA. **The challenge of reforming nutritional epidemiologic research.** *JAMA.*
774 2018; **320** (10): 969-970. <http://dx.doi.org/10.1001/jama.2018.11025>
775 48. **Global, regional, and national age-sex-specific mortality for 282 causes of death in**
776 **195 countries and territories, 1980-2017: a systematic analysis for the Global**
777 **Burden of Disease Study 2017.** *Lancet.* 2018; **392** (10159): 1736-1788.
778 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)32203-7/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32203-7/fulltext)
779 49. Afshin A, Sur PJ, Fay KA, et al. **Health effects of dietary risks in 195 countries, 1990-**
780 **2017: a systematic analysis for the Global Burden of Disease Study 2017.** *The Lancet.*
781 2019; **393** (10184): 1958-1972. [https://doi.org/10.1016/S0140-6736\(19\)30041-8](https://doi.org/10.1016/S0140-6736(19)30041-8)
782
783